Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Adderall XR Prescribers (US)

Articles with lock require a subscription to GLG News | Request a free trial
July 31, 2008
Be very careful
Analysis of: Blood pressure drugs may protect against Alzheimer's | www.washingtonpost.com
Author: GLG Expert Contributor
All is not as it seems when reported in the press, especially the non-scientific press.
Louis SanfilippoJuly 21, 2008
A Small Company, A Big Idea
Analysis of: TheraGenetics Licenses Intellectual Property Related To Predicting Patient Response To Antidepressant Therapy | www.medicalnewstoday.com
Author: Louis Sanfilippo, President, LCS Group, LLC
“Personalized medical diagnositics” looks to be evolving as a high impact area in neuropsychiatric drug development.  Such ‘genetic biomarker’ platforms, based on either pharmacogenetic profiles coming from DNA blueprints or gene products from a simple blood draw, aim to identify patients who are...
Louis SanfilippoJuly 3, 2008
One Drug, Many Uses -- Mostly a Very Good Idea
Analysis of: One drug, many uses. Good idea? | www.indystar.com
Author: Louis Sanfilippo, President, LCS Group, LLC
‘One drug, many uses’ can make lots of sense clinically and commercially.   Seeking additional FDA indications for a specific drug has obvious business benefits:  greater revenue stream, improved branding, potentially longer market exclusivity, greater franchising potential of the drug...
June 30, 2008
Medicare's Perfect Storm: Losing Primary Care
Analysis of: Medicare fees to doctors fall Tuesday | news.yahoo.com
Author: GLG Expert Contributor
Your mother and father will not get the compassion and care when they call for medical help .   It will not be available.  Your family physician was financially forced to leave.
Louis SanfilippoJune 30, 2008
Lundbeck Reveals Mechanism of Action of its “Mixed Serotonin Modulator and Stimulator” Antidepressant LuAA21004
Analysis of: Interim report for the first quarter of 2008 - strong growth in sales and profits | www.lundbeck.com
Author: Louis Sanfilippo, President, LCS Group, LLC
Lundbeck has now disclosed the mechanism of action of its “mixed serotonin modulator and stimulator,” albeit buried in a first quarter report.   Data on LuAA21004, Lundbeck’s lead antidepressant jointly in development with Takeda, was released at the Scandinavian College of Neuro-Psychopharmacology...
June 30, 2008
If you've done everything else, there is nothing else
Analysis of: Doctors Say Medication Is Overused in Dementia | www.nytimes.com
Author: GLG Expert Contributor
We need to look to the cause of why we prescribe antipsychotics to patients with dementia.  We have very few tools to use and sometimes these drugs are a necessity.
June 23, 2008
We can't afford to practice the "best" medicine
Analysis of: Most Doctors Aren’t Using Electronic Health Records | www.nytimes.com
Author: GLG Expert Contributor
This article clearly describes the Catch-22 in which most doctors, except for those employed by the large institutions, find themselves.  We cannot afford to practice the "best" medicine, and yet, if we could, we might well make fewer errors and make medical care for our patients more seamless. ...
Daniel WynnJune 5, 2008
Novartis and Multiple Sclerosis: A Major Commitment
Analysis of: Extavia® approved in E.U for treatment of multiple sclerosis, first in planned portfolio of therapies from Novartis | www.asia-manufacturing.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Extavia, Novartis' brand of  interferon beta 1b, has been approved for the  treatment of multiple sclerosis by the European Union.  With FTY72, Fingolimod, Novartis has the eye on filing NDA by the end of 2009.  While essentially identical to Bayer's Betaferon interferon beta 1b,...
Daniel WynnJune 2, 2008
Abbott's ABT-089 --Much More than a Treatment for ADHD
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
The data on ABT-089 in adults has been released with positive results, whereas the adolescent/childhood trial is on-going for this novel compound for ADHD.  The key difference is the potential to improve learning, not simply regain attention and lessen hyperactivity.
Louis SanfilippoMay 21, 2008
BrainCells Novel Antidepressant: Targeting Neurogenesis but not Serotonin?
Analysis of: BrainCells Inc. Initiates Phase 2 Clinical Trial With BCI-540 For Depression With Anxiety | www.medicalnewstoday.com
Author: Louis Sanfilippo, President, LCS Group, LLC
It’s not clear just how BrainCells’ BCI-540 works but the company claims the drug acts by way of promoting neurogenesis without an effect on serotonin neurotransmission.   While SSRI’s also promote neurogenesis, a downstream effect believed to favorably impact mood and anxiety, they obviously...

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 209

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses

Azilect
September 2, 2008

Byetta Saves Lives
September 2, 2008

The Devil Is in the Details
September 1, 2008

Dangers of Methadone Usage
August 28, 2008

Healthways A Market Downturn and Results
August 26, 2008

 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-09-05T17:45:16.330